Trials / Completed
CompletedNCT03677401
Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 295 (actual)
- Sponsor
- Vyne Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 5mg Serlopitant Tablets | Serlopitant Tablets |
| DRUG | Placebo Tablets | Placebo Tablets |
Timeline
- Start date
- 2018-08-29
- Primary completion
- 2020-01-09
- Completion
- 2020-02-06
- First posted
- 2018-09-19
- Last updated
- 2021-05-20
- Results posted
- 2020-10-28
Locations
40 sites across 3 countries: Austria, Germany, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03677401. Inclusion in this directory is not an endorsement.